Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy (LABD)

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: No intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT00791518

111891

Details and patient eligibility

About

A multicenter study to evaluate lung function and symptoms in subjects with COPD who have been on regular use of only one long-acting bronchodilator.

Enrollment: 1,084 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Cigarette smoking history-Current or ex-smokers (defined as stopped smoking for at least three months prior to the study visit)
• Established history of COPD as diagnosed by a physician
• Regular use (prescribed for use every day) of only one long-acting bronchodilator greater than or equal to one month before the study visit
• Ability to read, comprehend, and record information in the English language

Exclusion criteria

• Currently active asthma (receiving asthma therapy and or having asthma symptoms)
• Use of ipratropium/albuterol combination products greater than three times per day, use of inhaled corticosteroids, use of inhaled corticosteroid/long-acting beta-agonist combinations, theophylline preparations, or oral beta agonists within 3 months prior to the study visit
• Previous lung surgery
• Other respiratory disorders other than COPD
• Current alcohol, illegal drug, or solvent abuse
• Females with a positive urine pregnancy test at the study visit

Trial design

1,084 participants in 1 patient group

No group

Description:

No group

Treatment:

Drug: No intervention